

Appendix 4E (Rule 4.3A)**Results for announcement to the market**Name of entity: **Suda Limited** ABN 35 909 987 250

The current reporting period is the financial year ended 30 June 2015. The previous corresponding period is the financial year ended 30 June 2014.

Revenue / Profit	Movement	Change \$'000	Change %	30 June 2015 \$'000	30 June 2014 \$'000
Revenues from ordinary activities.	Down	3,025	35%	5,728	8,753
(Loss) from ordinary activities after tax attributable to members.	Down	1,315	64%	(3,367)	(2,052)
Net (loss) for the period attributable to members.	Down	1,315	64%	(3,367)	(2,052)

NTA Backing	30 June 2015 Cents	30 June 2014 Cents
Net tangible asset per security	0.55	0.36

Dividends

No interim dividends were paid and no final dividends are proposed.

Brief explanation of any of the figures reported above

The decrease in revenue by 35% was largely due to the performance of Suda's subsidiary company, Westcoast Surgical and Medical Supplies Pty Ltd (Westcoast). In the prior financial year, Westcoast had secured a contract for the provision of medical supplies to the detention centres which generated in excess of \$4m revenue. This contract generated negligible revenue for the reporting period.

The increase in the loss is largely due to decreased revenue and also the increase in costs incurred by Suda in relation to further development of its projects.

Audit Status

This preliminary report is based on financial statements that are in the process of being audited.

SUDA LTD
AND CONTROLLED ENTITIES

ABN: 35 090 987 250

Preliminary Final Report For The Year Ended
30 June 2015

SUDA LTD ABN 35 090 987 250 AND CONTROLLED ENTITIES
PRELIMINARY FINAL REPORT – APPENDIX 4E

Operating results

The consolidated loss of the consolidated group after providing for income tax attributable to owners of the parent entity amounted to \$3,367,191 (2014: \$2,051,794). The loss increased by 64% on the loss reported for the year ended 30 June 2014. Key developments during the year are explained below.

In April 2015, the Company successfully raised \$5.3 million via a heavily over-subscribed placement of 146.5 million fully paid ordinary shares at a price of \$0.036 per share ("Placement"). The Placement received strong support from leading domestic institutions in addition to a number of the Company's existing shareholders.

Product pipeline and subsidiary activities

ArTiMist™ oral spray for the treatment of paediatric malaria

SUDA's subsidiary company Malaria Research Company Pty Ltd (MRC) continued with its plan to expand the market of ArTiMist™ from the treatment of severe paediatric malaria to its use as an early interventional treatment when children first show signs of a malaria-like fever, before being referred to hospital. This would represent a significant expansion of the patient population that could benefit from the product and would substantially increase the product's commercial value. It is also an area of unmet medical need with no approved treatments.

SUDA is working with the Company's Clinical Advisory Board to design a clinical trial of ArTiMist™ in this pre-referral setting. The trial protocol will be presented to the World Health Organisation as a first step towards securing funding for the trial from global philanthropic groups.

In July 2015, the Company was granted a patent in Africa for its novel ArTiMist™ anti-malarial spray. The patent was issued by the African Regional Intellectual Property Organization (ARIPO), which is an intergovernmental organisation for cooperation among African states in intellectual property matters. ARIPO comprises 19 member states, including the major countries in malaria-endemic Sub-Saharan Africa.

SUD-001 sumatriptan oral spray for the treatment of migraine

SUDA submitted a Type C meeting briefing package to the US Food and Drug Administration (FDA) on 13 June 2015 containing details of the proposed pivotal study of SUD-001 and other activities intended to support a New Drug Application in the USA. On 6 August 2015, the FDA acknowledged SUDA's proposed development strategy and requested only minor justifications to the study design. Furthermore, the agency had no comments regarding SUDA's plans for chemistry, manufacturing, controls and non-clinical studies of SUD-001. The FDA also requested that SUDA submit a paediatric study plan in migraineurs aged 6-17 years who could benefit from SUDA's first-in-class oral-spray migraine therapy.

Under the acknowledged development plan, SUDA expects to save significant time and capital by avoiding the need to conduct costly efficacy studies prior to registration of SUD-001 in the USA.

SUD-003 sildenafil oral spray for the treatment of erectile dysfunction

SUDA is completing the development of a second-generation formulation of SUD-003 which includes flavouring, taste masking and optimal permeation characteristics that are designed to enhance further the onset of action and bioavailability. The Company is progressing discussions with prospective pharmaceutical partners in several major territories. In addition, the Company plans to meet with the FDA to discuss the Company's development plan which is intended to provide the data required to achieve registration of SUD-003.

Zolpimist oral spray for the treatment of insomnia and SUD-002 ondansetron for the treatment of chemotherapy-induced nausea and vomiting

In January 2015, SUDA entered into a cross-licence and collaboration agreement with Amherst Pharmaceuticals (Amherst), a US specialty pharmaceutical company based in New Jersey. Under the terms of the agreement, SUDA granted Amherst an exclusive licence to manufacture, develop and commercialise SUD-002 in the Americas, being North America and South America, and also South Africa. SUDA received an exclusive licence to manufacture, develop and commercialise Zolpimist® in all territories excluding the Americas and South Africa.

Westcoast Surgical & Medical Supplies (Westcoast)

Westcoast continues to be a strong player in the supply of medical consumables within the Aged Care, Allied Health, Mining and Hospital sectors in Western Australia.

**SUDA LTD ABN 35 090 987 250 AND CONTROLLED ENTITIES
PRELIMINARY FINAL REPORT – APPENDIX 4E**

Significant events

The significant events during the 2014-15 financial year were:

- i. Resignation of a Non-Executive Director

Mr Ken Robson resigned in August 2014.

- ii. Termination of the Bergen agreement

The Bergen facility was terminated in July 2014 and the final issue of shares to Bergen occurred in August 2014.

- iii. Exercise of options

The options that expired on 30 June 2014 were fully underwritten and the Company received \$1.4m and issued shares in respect of the exercise of options in July 2014.

- iv. ISO9001 certification

In September 2014, the Company was awarded ISO 9001:2008 certification for its quality management system.

- v. Cross-Licence agreement

In January 2015, the Company granted an exclusive licence to SUD-002 oral spray for Americas and Africa and in return SUDA received an exclusive global licence, excluding Americas and South Africa to Zolpimist® oral spray. Zolpimist® is a patented, fast-acting sedative for insomnia registered in the USA.

- vi. Successfully raised \$5.3m in a placement in April 2015.

The purpose of the capital raising was to add value to two of SUDA's first in-class patented oral sprays (SUD-001 for migraine and SUD-003 for erectile dysfunction); to support the Company's expanding business development activities; and to provide additional working capital.

- vii. Set up two clinical advisory boards (CAB)

In April 2015, the Company established a CAB for SUD-001 migraine oral spray and, in June 2015, established a CAB for SUD-003 erectile dysfunction oral spray.

Dividends Paid or Recommended

The Directors have recommended that no dividend be paid by the company in respect of the financial year ended 30 June 2015.

After Balance Date Events

- i. On 31 July 2015, SUDA announced that it was granted a patent in Africa for ArTiMist™ anti-malarial spray. The patent was issued by the African Regional Intellectual Property Organisation which comprises of 19 member states.
- ii. On 6 August 2015, SUDA announced it had received a written response from the FDA in relation to the development plan of SUDA's SUD-001 sumatriptan oral spray. The FDA acknowledged SUDA's proposed development strategy and requested only minor justifications to the study design.
- iii. On 24 August 2015, SUDA established a new fully owned subsidiary in the UK, Suda Europe Ltd, primarily to access grants available within the European Union.
- iv. On 26 August 2015, SUDA announced the acquisition of the 20% minority shareholding in SUDA's subsidiary company Malaria Research Company Pty Ltd (MRC). MRC owns the rights to the anti-malarial spray ArTiMist™. SUDA paid A\$1,200,000 for the 20% shareholding and was in full and final settlement of all outstanding liabilities between SUDA and the minority shareholder.

The Board thanks our shareholders for their ongoing support and looks forward to an exciting 2015/16 year.

SUDA LTD ABN: 35 090 987 250 AND CONTROLLED ENTITIES

**CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 JUNE 2015**

	Note	Group	
		2015	2014
		\$	\$
Revenues	2	5,727,589	8,753,164
Other income		136,416	-
Raw materials and consumables used	3	(5,022,888)	(6,112,710)
Employee benefits expense		(2,469,576)	(2,111,294)
Depreciation and amortisation expense		(123,652)	(67,147)
Finance costs	3	(156,200)	(158,641)
Other expenses	3	(2,127,937)	(2,544,595)
Loss before income tax		(4,036,248)	(2,241,223)
Income tax expense		657,917	180,373
Net loss for the period		(3,378,331)	(2,060,850)
Total comprehensive loss for the period		(3,378,331)	(2,060,850)
Loss and total comprehensive loss attributable to:			
Owners of the parent		(3,367,191)	(2,051,794)
Non-controlling interests		(11,140)	(9,056)
		(3,378,331)	(2,060,850)
Earnings per share			
Basic loss per share (cents)	4	(0.33)	(0.25)
Diluted loss per share (cents)	4	(0.33)	(0.25)

The accompanying notes form part of these financial statements.

SUDA LTD ABN: 35 090 987 250 AND CONTROLLED ENTITIES
CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2015

	Note	Group 2015 \$	2014 \$
CURRENT ASSETS			
Cash & cash equivalents		6,251,947	3,990,397
Trade & other receivables		1,318,621	930,565
Inventories		1,540,555	1,787,897
Other assets		233,257	776,273
TOTAL CURRENT ASSETS		9,344,380	7,485,132
NON-CURRENT ASSETS			
Property, plant and equipment		388,617	312,439
Intangible assets		13,087,746	12,549,453
TOTAL NON-CURRENT ASSETS		13,476,363	12,861,892
TOTAL ASSETS		22,820,743	20,347,024
CURRENT LIABILITIES			
Trade & other payables		1,795,156	2,480,468
Borrowings		1,725,000	-
TOTAL CURRENT LIABILITIES		3,520,156	2,480,468
NON-CURRENT LIABILITIES			
Borrowings		-	1,875,000
TOTAL NON-CURRENT LIABILITIES		-	1,875,000
TOTAL LIABILITIES		3,520,156	4,355,468
NET ASSETS		19,300,587	15,991,556
EQUITY			
Issued capital	6	55,573,622	48,944,557
Reserves		628,255	569,958
Accumulated losses		(38,932,438)	(35,565,247)
Equity attributable to the parent entity		17,269,439	13,949,268
Non-controlling interests		2,031,148	2,042,288
TOTAL EQUITY		19,300,587	15,991,556

The accompanying notes form part of these financial statements.

SUDA LTD ABN: 35 090 987 250 AND CONTROLLED ENTITIES

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2015

	Issued Capital \$	Accumulated Losses \$	Share-based Payments Reserve \$	Non- controlling interests \$	Total \$
Balance as at 1 July 2013	40,128,687	(33,513,453)	74,846	-	6,690,080
Non-controlling interest arising on project development of subsidiary company	-	-	-	2,051,344	2,051,344
Shares issued during the year	9,160,803	-	-	-	9,160,803
Share-based payments	-	-	495,112	-	495,112
Share issue costs	(344,933)	-	-	-	(344,933)
Loss for the year attributable to members of the parent entity	-	(2,051,794)	-	-	(2,051,794)
Loss for the year attributable to non-controlling interest	-	-	-	(9,056)	(9,056)
Balance as at 30 June 2014	48,944,557	(35,565,247)	569,958	2,042,288	15,991,556
Balance as at 1 July 2014	48,944,557	(35,565,247)	569,958	2,042,288	15,991,556
Shares issued during the year	6,925,386	-	-	-	6,925,386
Share-based payments	-	-	58,297	-	58,297
Transaction costs	(296,321)	-	-	-	(296,321)
Loss for the year attributable to members of the parent entity	-	(3,367,191)	-	-	(3,367,191)
Loss for the year attributable to non-controlling interest	-	-	-	(11,140)	(11,140)
Balance as at 30 June 2015	55,573,622	(38,932,438)	628,255	2,031,148	19,300,587

The accompanying notes form part of these financial statements.

**CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 JUNE 2015**

	Group	
	2015	2014
	\$	\$
CASH FLOWS FROM OPERATIONS		
Receipts from customers	6,298,415	8,848,985
Payments to suppliers	(9,734,732)	(11,554,803)
Receipts for R&D tax concession	188,290	174,217
Interest received	102,774	49,129
Interest paid	(113,630)	(132,158)
Net cash used in operations	<u>(3,258,883)</u>	<u>(2,614,629)</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(282,390)	(288,366)
Purchase of other non-current assets	(995,823)	(1,715,595)
Proceeds from sale of property, plant and equipment	5,455	-
Net cash used in investing activities	<u>(1,272,758)</u>	<u>(2,003,961)</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from share issues	7,089,512	6,393,655
Proceeds from borrowings	-	1,900,000
Payments for capital raising costs	(296,321)	(448,867)
Net cash provided by financing activities	<u>6,793,191</u>	<u>7,844,788</u>
Net increase / (decrease) in cash held	2,261,550	3,226,197
Cash at the beginning of period	3,990,397	752,619
Effect of exchange rates on cash holdings in foreign currencies	-	11,581
Cash at the end of period	<u><u>6,251,947</u></u>	<u><u>3,990,397</u></u>

Reconciliation of Cash and Cash Equivalents

	2015	2014
	\$	\$
Cash at bank and in hand	<u>6,251,947</u>	<u>3,990,397</u>
<i>Cash at the end of the period as shown in the cash flow statement is reconciled to items in the balance sheet as follows:</i>		
Cash and cash equivalents	<u>6,251,947</u>	<u>3,990,397</u>
	<u><u>6,251,947</u></u>	<u><u>3,990,397</u></u>

The accompanying notes form part of these financial statements.

SUDA LTD ABN: 35 090 987 250 AND CONTROLLED ENTITIES
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2015

The preliminary final report of the Company for the year ended 30 June 2015 comprises the Company and its controlled entities (the "Consolidated Entity" or "Group").

Note 1 Statement of Significant Accounting Policies

Basis of Preparation

The preliminary final report is presented in Australian dollars and has been prepared on an accrual basis and is based on historical cost basis except for selected current and non-current assets which are measured at fair value at reporting date.

The preliminary final report has been prepared in accordance with Australian Securities Exchange Listing Rules as they relate to Appendix 4E and in accordance with the recognition and measurement requirements of the Australian Accounting Standards (including Australian Accounting Interpretations) adopted by the AASB and the Corporations Act 2001.

As such, the preliminary final report does not include all notes of the type normally included within the annual financial report and therefore cannot be expected to provide a full understanding of the financial performance and financial position as the full financial report. It is recommended that the preliminary final report be considered together with any public announcements made by the Company in accordance with the continuous disclosure obligations of the Australian Securities Exchange Listing Rules.

Note 2 Revenue and Other Income

	Consolidated Group	
	2015	2014
	\$	\$
Sales Revenue		
— sale of goods	5,624,815	8,648,187
Other Revenue		
— interest received from other persons	102,774	104,977
Total Sales Revenue and Other Revenue	5,727,589	8,753,164
Other Income		
— gain on disposal of property, plant and equipment	5,455	-
— other income	130,961	-
Total Other Income	136,416	-

Note 3 Loss for the Year

	Consolidated Group	
	2015	2014
	\$	\$
(a) Expenses		
Cost of sales	4,709,576	6,067,337
Write-down inventories to net realisable value	182,615	-
Write-off of obsolete stock	130,697	62,314
	5,022,888	6,129,651
(b) Finance costs		
Interest expense on financial liabilities through profit or loss:		
— Other persons	156,200	158,642

SUDA LTD ABN: 35 090 987 250 AND CONTROLLED ENTITIES
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2015

Note 4 Earnings per Share

		Consolidated Group	
		2015	2014
		\$	\$
(a)	Reconciliation of earnings to profit or loss		
	Loss	(3,378,331)	(2,060,850)
	Earnings used to calculate basic EPS	(3,378,331)	(2,060,850)
	Earnings used in the calculation of dilutive EPS	(3,378,331)	(2,060,850)
		No.	No.
(b)	Weighted average number of ordinary shares outstanding during the year used in calculating basic EPS	1,015,727,042	835,955,632
		Options convertible to ordinary shares are not considered to be dilutive as their exercise will not result in diluted earnings per share.	

Note 5 Controlled Entities

Controlled Entities Consolidated	Country of Incorporation	Percentage Owned (%)	
		2015	2014
Subsidiaries of Suda Ltd:			
Westcoast Surgical and Medical Supplies Pty Ltd	Australia	100.00	100.00
Malaria Research Company Pty Ltd	Australia	80.00	80.00
Eastland CN Nominees Pty Ltd	Australia	100.00	100.00

Note 6 Issued Capital

	Consolidated Group	
	2015	2014
	\$	\$
Gross capital proceeds	57,870,852	50,945,466
Capital raising costs	(2,297,230)	(2,000,909)
1,136,010,587 (2014: 950,262,913) fully paid ordinary shares	55,573,622	48,944,557

Ordinary Shares

	No.	No.
At the beginning of reporting period	950,262,913	653,648,691
Shares issued 1 July 2013 to 30 June 2014		296,614,222
Shares issued during year:		
- share placement	146,467,100	
- exercise of options	30,700,000	
- conversion of convertible notes	5,009,820	
- settlement of interest on convertible notes	986,775	
- pursuant to Share Purchase and Convertible Security Agreement	2,583,979	
At reporting date	1,136,010,587	950,262,913